Lyme Disease vaccine

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.

Valneva's IXCHIQ vaccine demonstrates a sustained 98.3% sero-response rate one year after single vaccination in adolescents, supporting potential label extension.

The FDA has approved WGc-043, marking a historic milestone as the first mRNA vaccine developed for treating Epstein-Barr virus-related cancers. This groundbreaking development represents a significant advancement in oncology treatment, offering new therapeutic options for patients with advanced EBV-related malignancies.

Valneva and Pfizer's Lyme disease vaccine candidate, VLA15, demonstrated a strong immune response one month after a second booster dose in pediatric and adult populations.

Pfizer and Valneva have initiated a Phase 3 clinical trial for their Lyme disease vaccine candidate, VLA15, in areas highly endemic for the disease.